Up a level |
Zelniker, Thomas A, Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P, Heerspink, Hiddo HJL, Cahn, Avivit, Goodrich, Erica L, Im, Kyungah, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors)
(2021)
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiology, 6 (7).
pp. 801-810.
Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A et al (show 13 more authors)
(2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
CIRCULATION, 139 (22).
pp. 2528-2536.
Furtado, Remo HM, Raz, Itamar, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Aylward, Philip, Dalby, Anthony J et al (show 10 more authors)
(2022)
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
CIRCULATION, 145 (21).
pp. 1581-1591.
O'Donoghue, Michelle L, Kato, Eri T, Mosenzon, Ofri, Murphy, Sabina A, Cahn, Avivit, Herrera, Marisol, Tankova, Tsvetalina, Smahelova, Alena, Merlini, Piera, Gause-Nilsson, Ingrid et al (show 8 more authors)
(2021)
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
DIABETOLOGIA, 64 (6).
pp. 1226-1234.